TrialDiabetes technology & therapeutics2020

Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1).

Satish K Garg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.